Clinical trials
[PENDING VALIDATION — official introductory text for the UDIC Clinical Trials Unit.]
Featured clinical trials
Parkinson
PARAISO — BN44715
- Medical area
- Parkinson
- Sponsor laboratory
- ROCHE
- Study code
- BN44715
- Study name
- PARAISO
- Phase
- Phase III
- Intervention / treatment
- Prasinezumab / RO7046015 IV
- Description
- Phase III multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous Prasinezumab (RO7046015) in participants with early-stage Parkinson's disease.
- Status
- Ongoing
ARISE — CVN424-301
- Medical area
- Parkinson
- Sponsor laboratory
- CEREVANCE
- Study code
- CVN424-301
- Study name
- ARISE
- Phase
- Phase III
- Intervention / treatment
- CVN424
- Description
- Phase III multicenter, randomized, double-blind, placebo-controlled study of CVN424 in patients with Parkinson's disease with motor complications.
- Status
- Ongoing
Alzheimer
MINDSET — CN012-0051
- Medical area
- Alzheimer
- Sponsor laboratory
- BRISTOL MYERS SQUIBB
- Study code
- CN012-0051
- Study name
- MINDSET
- Phase
- Phase III
- Intervention / treatment
- KarXT (BMS-986510)
- Description
- Phase III study to evaluate the efficacy and safety of KarXT (BMS-986510) in cognitive impairment associated with Alzheimer's disease.
- Status
- Ongoing
TRONTIER 1 — WN45443
- Medical area
- Alzheimer
- Sponsor laboratory
- ROCHE
- Study code
- WN45443
- Study name
- TRONTIER 1
- Phase
- Phase III
- Intervention / treatment
- Trontinemab (RO7126209)
- Description
- Phase III multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy and safety of TRONTINEMAB (RO7126209) in patients with early Alzheimer's disease (from mild cognitive impairment to mild dementia due to Alzheimer's disease).
- Status
- Ongoing
TRAILBLAZER-ALZ 5 — I5T-MC-AACO
- Medical area
- Alzheimer
- Sponsor laboratory
- LILLY
- Study code
- I5T-MC-AACO
- Study name
- TRAILBLAZER-ALZ 5
- Phase
- Phase III
- Intervention / treatment
- Donanemab (LY3002813)
- Description
- Global study investigating the safety and efficacy of donanemab (LY3002813) in early symptomatic Alzheimer's disease.
- Status
- Ongoing
Active clinical trials
Parkinson
BEACON · DNLI-C-0009
- Medical area
- Parkinson
- Sponsor
- DENALI
- Study code
- DNLI-C-0009
- Study name
- BEACON
- Phase
- Phase IIa
- Intervention / treatment
- BIIB122
- Description
- Phase IIa multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and pharmacodynamic effects of BIIB122 in participants with LRRK2-associated Parkinson's disease (LRRK2-PD).
- Status
- Ongoing
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
LUNDBECK · LU18252A
- Medical area
- Parkinson
- Sponsor
- LUNDBECK
- Study code
- LU18252A
- Study name
- Not specified in source
- Phase
- Exploratory
- Intervention / treatment
- Lu AF28996
- Description
- Exploratory, open-label, interventional study investigating the safety, tolerability, pharmacokinetics and efficacy of Lu AF28996 in patients with Parkinson's disease.
- Status
- Ongoing
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
EXIST · BAN0805-201
- Medical area
- Parkinson
- Sponsor
- BIOARCTIC
- Study code
- BAN0805-201
- Study name
- EXIST
- Phase
- Phase IIa
- Intervention / treatment
- Exidavnemab
- Description
- Phase IIa randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and pharmacokinetics of multiple ascending doses of exidavnemab in patients with mild to moderate Parkinson's disease receiving stable medication for symptomatic Parkinson's disease.
- Status
- Ongoing
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
LUMA · 283PD201
- Medical area
- Parkinson
- Sponsor
- BIOGEN
- Study code
- 283PD201
- Study name
- LUMA
- Phase
- Phase IIb
- Intervention / treatment
- BIIB122
- Description
- Phase IIb multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants with Parkinson's disease.
- Status
- Ongoing
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
BouNDless · ND0612-007
- Medical area
- Parkinson
- Sponsor
- NEURODERM
- Study code
- ND0612-007
- Study name
- BouNDless
- Phase
- Not specified
- Intervention / treatment
- ND0612
- Description
- Multicenter, randomized, active-comparator, double-blind, double-dummy, parallel-group clinical study investigating the efficacy, safety and tolerability of continuous subcutaneous infusion of ND0612 compared with IR-LD/CD (immediate-release levodopa/carbidopa) in patients with Parkinson's disease who experience motor fluctuations.
- Status
- Ongoing
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
PADOVA · BN42358
- Medical area
- Parkinson
- Sponsor
- ROCHE
- Study code
- BN42358
- Study name
- PADOVA
- Phase
- Not specified
- Intervention / treatment
- Prasinezumab IV
- Description
- Multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early Parkinson's disease.
- Status
- Ongoing
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
PASADENA · BP39529
- Medical area
- Parkinson
- Sponsor
- ROCHE
- Study code
- BP39529
- Study name
- PASADENA
- Phase
- Phase II
- Intervention / treatment
- RO7046015 (PRX002) IV
- Description
- Phase II randomized, double-blind, placebo-controlled, 52-week study to evaluate the efficacy of intravenous RO7046015 (PRX002) in participants with early Parkinson's disease with a 52-week blinded extension.
- Status
- Ongoing
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Alzheimer
MINDSET 1 · CN012-0051
- Medical area
- Alzheimer
- Sponsor
- BRISTOL MYERS SQUIBB
- Study code
- CN012-0051
- Study name
- MINDSET 1
- Phase
- Phase III
- Intervention / treatment
- KarXT + KarX-EC
- Description
- Phase III randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of KarXT + KarX-EC in the treatment of cognitive impairment associated with mild to moderate Alzheimer's disease (MINDSET 1).
- Status
- Ongoing
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
RETAIN · 64042056ALZ2001
- Medical area
- Alzheimer
- Sponsor
- JANSSEN
- Code
- 64042056ALZ2001
- Study name
- RETAIN
- Phase
- Not specified
- Intervention / treatment
- JNJ-64042056
- Description
- Multicenter, randomized, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and immunogenicity of JNJ-64042056, an active immunotherapy targeting phosphorylated Tau, in participants with preclinical Alzheimer's disease.
- Status
- Recruiting
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
COGNIKET-MCI · 2302-CLI
- Medical area
- Alzheimer
- Sponsor
- NESTÉ HEALTH SCIENCES
- Study code
- 2302-CLI
- Study name
- COGNIKET-MCI
- Phase
- Not specified
- Intervention / treatment
- Triglicéridos de cadena media cetogénicos (kMCT) y vitaminas B
- Description
- Prospective, randomized, double-blind, placebo-controlled, multicenter, multinational, pivotal trial to study the effects of a nutritional intervention of ketogenic medium-chain triglycerides (kMCT) and B vitamins on cognitive functioning in older adults with mild cognitive impairment.
- Status
- Ongoing
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
BrainShuttle AD · BP42155
- Medical area
- Alzheimer
- Sponsor
- ROCHE
- Study code
- BP42155
- Study name
- BrainShuttle AD
- Phase
- Not specified
- Intervention / treatment
- Ro7126209
- Description
- Randomized, double-blind, placebo-controlled, multiple ascending-dose, parallel-group study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of Ro7126209 following intravenous infusion in patients with prodromal or mild to moderate Alzheimer's disease.
- Status
- Ongoing
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
ALTITUDE-AD · ACU193-201
- Medical area
- Alzheimer
- Sponsor
- ACUMEN
- Study code
- ACU193-201
- Study name
- ALTITUDE-AD
- Phase
- Phase II/III
- Intervention / treatment
- ACU193 IV
- Description
- Phase II/III adaptive-design, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of intravenous ACU193 in early Alzheimer's disease.
- Status
- Ongoing
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
TARGET TAU-1 · CN008-003
- Medical area
- Alzheimer
- Sponsor
- BRISTOL MYERS SQUIBB
- Code
- CN008-003
- Study name
- TARGET TAU-1
- Phase
- Not specified
- Intervention / treatment
- BMS-986446
- Description
- Global, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of BMS-986446, an anti-MTBR Tau monoclonal antibody, in participants with early Alzheimer's disease (TargetTau-1).
- Status
- Recruiting
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
GABRIELLA · BP44745
- Medical area
- Alzheimer
- Sponsor
- ROCHE
- Study code
- BP44745
- Study name
- GABRIELLA
- Phase
- Phase II
- Intervention / treatment
- RO7269162
- Description
- Phase II randomized, double-blind, placebo-controlled, multiple-dose, multicenter, parallel-group study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7269162 following daily oral administration in participants at risk or in the prodromal stage of Alzheimer's disease.
- Status
- Ongoing
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
EVOKE · NN6535-4730
- Medical area
- Alzheimer
- Sponsor
- NOVO NORDISK
- Study code
- NN6535-4730
- Study name
- EVOKE
- Phase
- Phase III
- Intervention / treatment
- Semaglutida oral
- Description
- Phase III randomized, double-blind, placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer's disease.
- Status
- Ongoing
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
EVOKE Plus · NN6535-4725
- Medical area
- Alzheimer
- Sponsor
- NOVO NORDISK
- Study code
- NN6535-4725
- Study name
- EVOKE Plus
- Phase
- Not specified
- Intervention / treatment
- Semaglutida oral
- Description
- Randomized, double-blind, placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer's disease.
- Status
- Ongoing
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
AuTonomy · 63733657ALZ2002
- Medical area
- Alzheimer
- Sponsor
- JANSSEN
- Study code
- 63733657ALZ2002
- Study name
- AuTonomy
- Phase
- Phase II
- Intervention / treatment
- JNJ-63733657
- Description
- Phase II multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of JNJ-63733657, an anti-Tau monoclonal antibody, in patients with early Alzheimer's disease.
- Status
- Ongoing
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
Clinical trials in other therapeutic areas
FLEX · IMVT-1401-301
- Medical area
- Miastenia grave generalizada
- Sponsor
- IMMUNOVANT
- Code
- IMVT-1401-301
- Study name
- FLEX
- Phase
- Phase III
- Intervention / treatment
- Batoclimab
- Description
- Phase III multicenter, randomized, quadruple-blind, placebo-controlled study to evaluate the efficacy and safety of batoclimab as induction and maintenance therapy in adult participants with generalized myasthenia gravis (MMG). PI: Dr. Josep Gámez.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
ALLEVIA-2 · NOE-TTS-201
- Medical area
- Síndrome de Tourette
- Sponsor
- NOEMA
- Code
- NOE-TTS-201
- Study name
- ALLEVIA-2
- Phase
- Phase II/III
- Intervention / treatment
- Gemlapodect
- Description
- Prospective, multicenter, Phase II/III, double-blind, placebo-controlled, twelve-week study to evaluate the efficacy and safety of Gemlapodect in adult and adolescent patients with Tourette syndrome.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
FALCON · KL1333-2020-104A
- Medical area
- Enfermedad mitocondrial primaria
- Sponsor
- ABLIVA
- Code
- KL1333-2020-104A
- Study name
- FALCON
- Phase
- Phase III
- Intervention / treatment
- KL1333
- Description
- Adaptive interventional study, randomized, double-blinded and parallel-group, with flexible dosing and placebo comparator, to evaluate the efficacy of KL1333 in adult patients with primary mitochondrial disease (EMP). PI: Dr. Josep Gámez.
- Status
- Recruiting
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
PROPEL · IMVT-1402-3101
- Medical area
- Miastenia grave generalizada
- Sponsor
- IMMUNOVANT
- Code
- IMVT-1402-3101
- Study name
- PROPEL
- Phase
- [PENDIENTE VALIDACIÓN]
- Intervention / treatment
- [PENDIENTE VALIDACIÓN]
- Description
- [PENDIENTE VALIDACIÓN]
- Status
- Recruiting
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
KEDRION · KB071
- Medical area
- Otras áreas
- Sponsor
- KEDRION
- Code
- KB071
- Study name
- Not specified in source
- Phase
- [PENDIENTE VALIDACIÓN]
- Intervention / treatment
- [PENDIENTE VALIDACIÓN]
- Description
- [PENDIENTE VALIDACIÓN]
- Status
- Recruiting
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
Future projects
NOVARTIS · CVHB937A12201
- Medical area
- Alzheimer
- Sponsor
- NOVARTIS
- Code
- CVHB937A12201
- Study name
- Not specified in source
- Phase
- Not specified
- Intervention / treatment
- VHB937
- Description
- Randomized, placebo-controlled, parallel-group, 72-week study to evaluate the efficacy and safety of VHB937 in participants with early Alzheimer's disease, followed by an extension.
- Status
- Future trial
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
NOVARTIS
- Medical area
- Alzheimer
- Sponsor
- NOVARTIS
- Code
- Not specified in source
- Study name
- Not specified in source
- Phase
- [PENDIENTE VALIDACIÓN]
- Intervention / treatment
- [PENDIENTE VALIDACIÓN]
- Description
- [PENDIENTE VALIDACIÓN]
- Status
- Future trial
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
mEADow · BP45770
- Medical area
- Parkinson
- Sponsor
- ROCHE
- Code
- BP45770
- Study name
- mEADow
- Phase
- [PENDIENTE VALIDACIÓN]
- Intervention / treatment
- [PENDIENTE VALIDACIÓN]
- Description
- [PENDIENTE VALIDACIÓN]
- Status
- Future trial
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
ALNYLAM · ALN-5288-001
- Medical area
- Alzheimer
- Sponsor
- ALNYLAM
- Code
- ALN-5288-001
- Study name
- Not specified in source
- Phase
- [PENDIENTE VALIDACIÓN]
- Intervention / treatment
- [PENDIENTE VALIDACIÓN]
- Description
- [PENDIENTE VALIDACIÓN]
- Status
- Future trial
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
NOVARTIS · CNIO752A12301
- Medical area
- Alzheimer
- Sponsor
- NOVARTIS
- Code
- CNIO752A12301
- Study name
- Not specified in source
- Phase
- [PENDIENTE VALIDACIÓN]
- Intervention / treatment
- [PENDIENTE VALIDACIÓN]
- Description
- [PENDIENTE VALIDACIÓN]
- Status
- Future trial
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
Historical trials
Closed, completed or archived studies. Kept separate from active trials.
TemPo-4 · CVL-751-PD-004
- Medical area
- Parkinson
- Sponsor
- Cerevel
- Study code
- CVL-751-PD-004
- Study name
- TemPo-4
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- A 58-week open-label trial of Tavapadon in Parkinson's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
TemPo-1 · CVL-751-PD-001
- Medical area
- Parkinson
- Sponsor
- Cerevel
- Study code
- CVL-751-PD-001
- Study name
- TemPo-1
- Phase
- Phase 3
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- A 27-week phase 3, double-blind, randomized, placebo-controlled, parallel-group trial of the efficacy, safety and tolerability of two fixed doses of tavapadon in early Parkinson's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Annovis · ANVS-22001
- Medical area
- PARKINSON
- Sponsor
- Annovis
- Code
- ANVS-22001
- Study name
- Not specified in source
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- A prospective 6-month, randomized, double-blind, placebo-controlled clinical trial investigating the efficacy, safety and tolerability of two different doses of buntanetap versus placebo in patients with early Parkinson's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
PROSEEK · SPARC CRL18-06
- Medical area
- Parkinson
- Sponsor
- Sun Pharma
- Study code
- SPARC CRL18-06
- Study name
- PROSEEK
- Phase
- Phase 2
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- A phase 2, randomized, double-blind, placebo-controlled study with K0706 in patients with early Parkinson's disease to evaluate the safety and efficacy of Abl tyrosine kinase inhibition.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
TemPo-3 · CVL-751-PD-003
- Medical area
- Parkinson
- Sponsor
- Cerevel
- Study code
- CVL-751-PD-003
- Study name
- TemPo-3
- Phase
- Phase 3
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- A 27-week phase 3, double-blind, randomized, placebo-controlled, parallel-group, flexible-dose trial to evaluate the efficacy, safety and tolerability of tavapadon as add-on therapy for Parkinson's disease in adults with motor fluctuations treated with levodopa.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
REASON · 254PD101
- Medical area
- Parkinson
- Sponsor
- Biogen
- Study code
- 254PD101
- Study name
- REASON
- Phase
- Phase 1
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- A phase 1 single and multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of BIIB094 administered intrathecally in adults with Parkinson's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
ASTORIA · JM010-CS03
- Medical area
- PARKINSON
- Sponsor
- Contera
- Code
- JM010-CS03
- Study name
- ASTORIA
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Randomized, double-blind, placebo-controlled, parallel-group study in patients with Parkinson's disease with moderate to severe dyskinesia to evaluate the efficacy, safety and tolerability of two dose combinations of JM-010.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
LIGHTHOUSE · 283PD302
- Medical area
- PARKINSON
- Sponsor
- Biogen
- Code
- 283PD302
- Study name
- LIGHTHOUSE
- Phase
- Phase 3
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- A Phase III multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122/DNL151 in participants with Parkinson's disease and pathogenic LRRK2 variants.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
Sunovion · CTH-301
- Medical area
- PARKINSON
- Sponsor
- Sunovion
- Code
- CTH-301
- Study name
- Not specified in source
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Open-label extension study with sublingual apomorphine to evaluate its long-term safety (over 3 years).
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
Farma Two · P2B001-003
- Medical area
- PARKINSON
- Sponsor
- Farma Two
- Code
- P2B001-003
- Study name
- Not specified in source
- Phase
- Phase 3
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- A 12-week Phase III multicenter, multinational, randomized, double-blind, double-dummy, parallel-group study to determine the efficacy, safety and tolerability of once-daily P2B001 compared with its individual components and a pramipexole ER titration arm in subjects with early Parkinson's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
Impax · IPX203-B16-03
- Medical area
- PARKINSON
- Sponsor
- Impax
- Code
- IPX203-B16-03
- Study name
- Not specified in source
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- An open-label extension study comparing the safety and efficacy of IPX203 with immediate-release carbidopa-levodopa in patients with Parkinson's disease with motor fluctuations.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
RISE-PD · IPX203-B16-02
- Medical area
- Parkinson
- Sponsor
- Impax
- Study code
- IPX203-B16-02
- Study name
- RISE-PD
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Randomized controlled study comparing the safety and efficacy of IPX203 with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Sunovion · CTH-302
- Medical area
- PARKINSON
- Sponsor
- Sunovion
- Code
- CTH-302
- Study name
- Not specified in source
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- An open-label, randomized, crossover trial using a single-blind evaluator to assess APL-130277 compared with subcutaneous apomorphine in levodopa-responsive subjects with Parkinson's disease complicated by motor fluctuations.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
SPARK · 228PD201
- Medical area
- Parkinson
- Sponsor
- Biogen
- Study code
- 228PD201
- Study name
- SPARK
- Phase
- Phase 2
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of BIIB037 in subjects with early symptomatic Parkinson's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
AMBLED · PXT-CL17-001
- Medical area
- PARKINSON
- Sponsor
- Prexton
- Code
- PXT-CL17-001
- Study name
- AMBLED
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- A multicenter, double-blind, randomized, placebo-controlled, parallel-arm Phase IIa trial to evaluate the efficacy, safety and tolerability of 28-day oral treatment with PXT002331 in reducing motor complications of levodopa therapy in Parkinson's disease patients experiencing end-of-dose wearing off and levodopa-induced dyskinesia.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
Intec Pharma · IN11004
- Medical area
- PARKINSON
- Sponsor
- Intec Pharma
- Code
- IN11004
- Study name
- Not specified in source
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase III multicenter, randomized, double-blind, double-dummy, active-controlled study comparing the efficacy and safety of gastric-retention and controlled-release accordion pill carbidopa/levodopa (AP-CD/LD) with immediate-release CD/LD in patients with fluctuating Parkinson's disease. Includes IN11004E extension.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
Biotie/Acorda · TOZ CL-05
- Medical area
- PARKINSON
- Sponsor
- Biotie/Acorda
- Code
- TOZ CL-05
- Study name
- Not specified in source
- Phase
- Phase 3
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase III multicenter, randomized, double-blind, placebo-controlled study with an open-label extension phase to determine the efficacy and safety of tozadenant as adjunctive therapy in levodopa-treated patients with Parkinson's disease experiencing end-of-dose wearing-off.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
Civitas/Acorda · CVT-301-004
- Medical area
- PARKINSON
- Sponsor
- Civitas/Acorda
- Code
- CVT-301-004
- Study name
- Not specified in source
- Phase
- Phase 3
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase III randomized, double-blind, placebo-controlled study investigating the efficacy and safety of CVT-301 (levodopa inhalation powder) in Parkinson's disease patients with motor response fluctuations (OFF phenomena) (SPAN-PD™).
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
Civitas/Acorda · CVT-301-005
- Medical area
- PARKINSON
- Sponsor
- Civitas/Acorda
- Code
- CVT-301-005
- Study name
- Not specified in source
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Randomized study investigating the safety and effect of CVT301 (inhaled levodopa) compared with standard treatment in Parkinson's disease with motor fluctuations (off).
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
ALLAYD-II · OS320-3006
- Medical area
- PARKINSON
- Sponsor
- Osmotica
- Code
- OS320-3006
- Study name
- ALLAYD-II
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Multicenter, randomized, placebo-controlled, double-blind clinical trial to evaluate the efficacy and safety of extended-release amantadine over 26 weeks in Parkinson's disease with levodopa-induced dyskinesia.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
ALLAYD-I · OS320-3005
- Medical area
- PARKINSON
- Sponsor
- Osmotica
- Code
- OS320-3005
- Study name
- ALLAYD-I
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Multicenter, randomized, placebo-controlled, double-blind clinical trial to evaluate the efficacy and safety of extended-release amantadine over 16 weeks in Parkinson's disease with levodopa-induced dyskinesia.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
Bial · BIA 91067-301
- Medical area
- PARKINSON
- Sponsor
- Bial
- Code
- BIA 91067-301
- Study name
- Not specified in source
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase III study of the efficacy and safety of BIA 91067-301 in patients with idiopathic Parkinson's disease with wearing-off phenomenon treated with levodopa and a dopa decarboxylase inhibitor (DDCI): multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group clinical trial.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
Mundipharma · OXN 2504
- Medical area
- PARKINSON
- Sponsor
- Mundipharma
- Code
- OXN 2504
- Study name
- Not specified in source
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase III multicenter, randomized, double-blind, placebo-controlled study investigating the efficacy and tolerability of OXN PR for the treatment of severe pain associated with Parkinson's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
Novartis · CAFQ056 A2299
- Medical area
- PARKINSON
- Sponsor
- Novartis
- Code
- CAFQ056 A2299
- Study name
- Not specified in source
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase II/III open-label treatment study evaluating the safety, tolerability and efficacy of AFQ056 in levodopa-induced dyskinesias in patients with Parkinson's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
Novartis · CAFQ056 A2223
- Medical area
- PARKINSON
- Sponsor
- Novartis
- Code
- CAFQ056 A2223
- Study name
- Not specified in source
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- 13-week Phase II multicenter, double-blind, placebo-controlled, fixed-dose study evaluating the efficacy and safety of modified-release AFQ056 in reducing moderate to severe levodopa-induced dyskinesias in patients with Parkinson's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
Novartis · CAFQ056 A2222
- Medical area
- PARKINSON
- Sponsor
- Novartis
- Code
- CAFQ056 A2222
- Study name
- Not specified in source
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- 12-week Phase II multicenter, double-blind, placebo-controlled, fixed-dose study evaluating the efficacy and safety of AFQ056 in reducing moderate to severe levodopa-induced dyskinesias in patients with Parkinson's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
Merck Schering Plough · P05664
- Medical area
- PARKINSON
- Sponsor
- Merck Schering Plough
- Code
- P05664
- Study name
- Not specified in source
- Phase
- Phase 3
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase III efficacy and safety study, double-blind, placebo- and active-treatment-controlled dose-ranging study of preladenant in subjects with early Parkinson's disease. PI: Dr. E. Balaguer. Hospital General de Catalunya. PI: Dr. A. Ugarte. Hospital Sant Joan de Déu, Manresa.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
Merck Schering Plough · P06153
- Medical area
- PARKINSON
- Sponsor
- Merck Schering Plough
- Code
- P06153
- Study name
- Not specified in source
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase III active-treatment-controlled, double-blind, double-dummy extension study of preladenant in subjects with moderate to severe Parkinson's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
Merck Schering Plough · P04938
- Medical area
- PARKINSON
- Sponsor
- Merck Schering Plough
- Code
- P04938
- Study name
- Not specified in source
- Phase
- Phase 3
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- 12-week Phase III efficacy and safety study, double-blind, placebo- and active-treatment-controlled, of preladenant in subjects with moderate to severe Parkinson's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
Schwarz Biosciences (UCB) · SP1066
- Medical area
- PARKINSON
- Sponsor
- Schwarz Biosciences (UCB)
- Study code
- SP1066
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Multicenter, randomized, double-blind, two-way cross-over study comparing the adhesiveness of two different rotigotine patch formulations in subjects with Parkinson's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Merck Serono · OLE28850
- Medical area
- PARKINSON
- Sponsor
- Merck Serono
- Study code
- OLE28850
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase III open-label study to determine the long-term safety of safinamide in patients with Parkinson's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Merck Serono · EMR 701165-024
- Medical area
- PARKINSON
- Sponsor
- Merck Serono
- Study code
- EMR 701165-024
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase II randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effect of safinamide on cognition in non-demented patients with idiopathic Parkinson's disease and cognitive impairment.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Impax Pharmaceuticals · IPX066-B09-03
- Medical area
- PARKINSON
- Sponsor
- Impax Pharmaceuticals
- Study code
- IPX066-B09-03
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Study evaluating the safety and efficacy of IPX066 in advanced Parkinson's disease. Open-label extension.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Impax Pharmaceuticals · IPX066-B09-02
- Medical area
- PARKINSON
- Sponsor
- Impax Pharmaceuticals
- Study code
- IPX066-B09-02
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Study evaluating the safety and efficacy of IPX066 in advanced Parkinson's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Novartis · CAFQ056A2208
- Medical area
- PARKINSON
- Sponsor
- Novartis
- Study code
- CAFQ056A2208
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- 13-week multicenter, double-blind, placebo-controlled, fixed-dose study evaluating the efficacy and safety of AFQ056 in reducing moderate to severe levodopa-induced dyskinesias in patients with Parkinson's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Acadia · ACP-103-014
- Medical area
- PARKINSON
- Sponsor
- Acadia
- Study code
- ACP-103-014
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Multicenter, placebo-controlled, double-blind trial examining the safety and efficacy of ACP-103 in the treatment of psychosis in Parkinson's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Boehringer-Ingelheim · BI 248.634
- Medical area
- PARKINSON
- Sponsor
- Boehringer-Ingelheim
- Study code
- BI 248.634
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Long-term open-label safety study of pramipexole extended release (ER) in patients with advanced Parkinson's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Boehringer-Ingelheim · BI 248.525
- Medical area
- PARKINSON
- Sponsor
- Boehringer-Ingelheim
- Study code
- BI 248.525
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Randomized, double-blind, double-dummy, placebo-controlled, three parallel-group study comparing the efficacy, safety and tolerability of pramipexole ER versus placebo and pramipexole IR, administered orally during a 26-week maintenance phase in levodopa-treated patients with advanced Parkinson's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
GSK · RO105323
- Medical area
- PARKINSON
- Sponsor
- GSK
- Study code
- RO105323
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Clinical trial evaluating the efficacy and safety of extended-release pramipexole versus immediate-release pramipexole and placebo in advanced Parkinson's disease with motor fluctuations and dyskinesias.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Schwarz Pharma · SP 873
- Medical area
- PARKINSON
- Sponsor
- Schwarz Pharma
- Study code
- SP 873
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- International proof-of-concept study evaluating the efficacy and safety of rotigotine administered intranasally in advanced Parkinson's disease with motor fluctuations and dyskinesias.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Schwarz Pharma · SP 833
- Medical area
- PARKINSON
- Sponsor
- Schwarz Pharma
- Study code
- SP 833
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Multicenter open-label extension clinical trial evaluating the efficacy, tolerability and safety of rotigotine administered as rotigotine patches in patients with early Parkinson's disease and sleep disorders.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Schwarz Pharma · SP 825
- Medical area
- PARKINSON
- Sponsor
- Schwarz Pharma
- Study code
- SP 825
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Multicenter, randomized, ropinirole-controlled clinical trial evaluating the efficacy, tolerability and safety of rotigotine administered as rotigotine patches in patients with early Parkinson's disease and sleep disorders.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Schwarz Pharma · SP 516
- Medical area
- PARKINSON
- Sponsor
- Schwarz Pharma
- Study code
- SP 516
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Multicenter open-label extension clinical trial evaluating the efficacy, tolerability and safety of rotigotine administered as rotigotine patches in patients with advanced Parkinson's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Schwarz Pharma · SP 515
- Medical area
- PARKINSON
- Sponsor
- Schwarz Pharma
- Study code
- SP 515
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Multicenter, randomized, double-blind clinical trial controlled with placebo and pramipexole evaluating the efficacy, tolerability and safety of rotigotine administered as rotigotine patches in patients with advanced Parkinson's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Novartis · CENA 713-IA 05
- Medical area
- PARKINSON
- Sponsor
- Novartis
- Study code
- CENA 713-IA 05
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 24-week study assessing the efficacy, tolerability and safety of 3–12 mg/day Exelon (rivastigmine) capsules in patients with probable vascular dementia.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Novartis · CENA 713-B2311 E1
- Medical area
- PARKINSON
- Sponsor
- Novartis
- Study code
- CENA 713-B2311 E1
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- 24-week open-label treatment extension study of a multicenter clinical trial evaluating the efficacy, tolerability and safety of 3–12 mg/day Exelon (rivastigmine) capsules in patients with dementia due to Parkinson's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Novartis · CENA 713-B2311
- Medical area
- PARKINSON
- Sponsor
- Novartis
- Study code
- CENA 713-B2311
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Multicenter, prospective, randomized, double-blind, parallel, placebo-controlled, 24-week study evaluating the efficacy, tolerability and safety of 3–12 mg/day Exelon (rivastigmine) capsules in patients with dementia due to Parkinson's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Novartis · CCOM998 IA04
- Medical area
- PARKINSON
- Sponsor
- Novartis
- Study code
- CCOM998 IA04
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Multicenter, open-label study evaluating different dose regimens of the levodopa / DDCI / entacapone combination in Parkinson's disease patients beginning to experience end-of-dose deterioration symptoms.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Schering AG · Lisuride
- Medical area
- Parkinson
- Sponsor
- Schering AG
- Study code
- Not specified in source
- Study name
- Lisuride
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Continuous subcutaneous administration (12h/24h) in advanced Parkinson's disease with complex fluctuations and dyskinesias, via subcutaneous infusion pump of Lisuride. PI: Dr. E. Tolosa. Hospital Clínic (Barcelona).
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
ASCENT-2 · PRX012-102
- Medical area
- Alzheimer
- Sponsor
- PROTHENA
- Code
- PRX012-102
- Study name
- ASCENT-2
- Phase
- Phase 1
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase I randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of PRX012 in subjects with Alzheimer's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
ABRO-AD · M23-515
- Medical area
- Alzheimer
- Sponsor
- ABBVIE
- Code
- M23-515
- Study name
- ABRO-AD
- Phase
- Phase 2B
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase IIb randomized, double-blind, placebo-controlled, dose-finding study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of ABBV-552 in participants with mild Alzheimer's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
TOGETHER · AH003
- Medical area
- Alzheimer
- Sponsor
- UCB
- Code
- AH003
- Study name
- TOGETHER
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Placebo-controlled, patient- and investigator-blind study to evaluate the efficacy, safety and tolerability of bepranemab (UCB0107) in patients with prodromal to mild Alzheimer's disease (AD), followed by an open-label extension period. Phase II.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
CLARITY · BAN2401-G000-301
- Medical area
- Alzheimer
- Sponsor
- EISAI
- Code
- BAN2401-G000-301
- Study name
- CLARITY
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- A placebo-controlled, double-blind, parallel-group, 18-month study with an open-label extension phase to confirm the safety and efficacy of BAN2401 in subjects with early Alzheimer's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
OLE · BAN2401-G000-201
- Medical area
- Alzheimer
- Sponsor
- EISAI
- Code
- BAN2401-G000-201
- Study name
- OLE
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Placebo-controlled, double-blind, parallel-group dose-regimen finding study with Bayesian adaptive randomization design and an open-label extension phase to evaluate the safety, tolerability and efficacy of BAN2401 in subjects with early Alzheimer's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
TRAILRUNNER-ALZ 2 · J1G-MC-LAKD
- Medical area
- Alzheimer
- Sponsor
- LILLY
- Study code
- J1G-MC-LAKD
- Study name
- TRAILRUNNER-ALZ 2
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Evaluation of the safety and efficacy of subcutaneous remternetug in early symptomatic Alzheimer's disease. Compound: Remternetug (LY3372993). Study phase: 3.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
BIAL · BIA 28-6156-201
- Medical area
- Alzheimer
- Sponsor
- BIAL
- Code
- BIA 28-6156-201
- Study name
- Not specified in source
- Phase
- Phase 2
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Un Estudio de Fase 2, Aleatorizado, Doble Ciego, Controlado con Placebo para Evaluar la Eficacia, Seguridad y Tolerabilidad del BIA 28 6156 en Sujetos con Enfermedad de Parkinson con una Variante Patogénica en el Gen de la Glucocerebrosidasa (GBA1).
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
NEURIMMUNE · NI004-201
- Medical area
- Alzheimer
- Sponsor
- NEURIMMUNE
- Study code
- NI004-201
- Study name
- Not specified in source
- Phase
- Phase 1B/2
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase 1b/2a multicenter, randomized, parallel-group, double-blind, placebo-controlled trial evaluating the safety and tolerability, as well as the efficacy, of the selective orthosteric M1 muscarinic receptor agonist NI004 versus placebo in mild to moderate Alzheimer's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
HARBOR · M22-721
- Medical area
- Alzheimer
- Sponsor
- ABBVIE
- Code
- M22-721
- Study name
- HARBOR
- Phase
- Phase 1B/2
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Study Protocol M22-721 Alzheimer's Disease: A Phase 1b/2a multiple ascending dose and proof-of-concept study of ABBV-916.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
ASPECT · 20-AVP-786-307
- Medical area
- Alzheimer
- Sponsor
- AVANIR
- Code
- 20-AVP-786-307
- Study name
- ASPECT
- Phase
- Phase 3
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase III multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM] / quinidine sulfate [Q]) for the treatment of agitation in patients with Alzheimer's type dementia.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
LUCIDITY · TRx-237-039
- Medical area
- Alzheimer
- Sponsor
- TauRx Therapeutics
- Code
- TRx-237-039
- Study name
- LUCIDITY
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- A 9-month, three-arm, randomized, double-blind, placebo-controlled brain imaging, safety and efficacy study of LMTM in subjects with early Alzheimer's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
GRADUATE · WN29922
- Medical area
- Alzheimer
- Sponsor
- ROCHE
- Code
- WN29922
- Study name
- GRADUATE
- Phase
- Phase 3
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- A Phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group efficacy and safety study of gantenerumab in patients with early Alzheimer's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
GAIN · COR388-010
- Medical area
- Alzheimer
- Sponsor
- CORTEXYME
- Code
- COR388-010
- Study name
- GAIN
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Randomized, double-blind, placebo-controlled study of COR388HCI in subjects with Alzheimer's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
ACADIA · ACP-103-045
- Medical area
- Alzheimer
- Sponsor
- ACADIA
- Study code
- ACP-103-045
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Double-blind, placebo-controlled relapse prevention study of pimavanserin in hallucinations and delusions associated with dementia-related psychosis.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
BOEHRINGER-INGELHEIM · 1346.23
- Medical area
- Alzheimer
- Sponsor
- BOEHRINGER-INGELHEIM
- Study code
- 1346.23
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Multicenter, double-blind, parallel-group, randomized controlled study investigating the efficacy, safety and tolerability of orally administered BI 425809 during a 12-week treatment period compared to placebo in patients with cognitive impairment due to Alzheimer's disease. PI: Dr. E. Balaguer. Hospital General de Catalunya. PI: Dr. A. Ugarte / Dr. Antonio Hernández. Hospital Sant Joan de Déu, Manresa.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
MISSION AD · E2609-G000-301
- Medical area
- Alzheimer
- Sponsor
- EISAI
- Code
- E2609-G000-301
- Study name
- MISSION AD
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- A placebo-controlled, double-blind, parallel-group, 24-month study to evaluate the efficacy and safety of E2609 in subjects with early Alzheimer's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
HEPTARES · HTL0018318-202
- Medical area
- Alzheimer
- Sponsor
- HEPTARES
- Study code
- HTL0018318-202
- Study name
- Not specified in source
- Phase
- Phase 1B
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase 1b randomized, double-blind, placebo-controlled, parallel-group, multicenter study to determine the safety and tolerability of HTL0018318 in subjects with mild to moderate Alzheimer's disease receiving donepezil or donepezil / memantine.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
EARLY · 54861911ALZ2003
- Medical area
- Alzheimer
- Sponsor
- JANSSEN
- Code
- 54861911ALZ2003
- Study name
- EARLY
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase IIb/III randomized, double-blind, placebo-controlled, parallel-group, multicenter study investigating the efficacy and safety of JNJ-54861911 in subjects who are asymptomatic at risk for developing Alzheimer's dementia. PI: Dr. A. Ugarte. Hospital Sant Joan de Déu, Manresa.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
AXOVANT · RVT-101-3002
- Medical area
- Alzheimer
- Sponsor
- AXOVANT
- Study code
- RVT-101-3002
- Study name
- Not specified in source
- Phase
- Phase 3
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Open-label extension of a phase 3, double-blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
AXOVANT · RVT-101-3001
- Medical area
- Alzheimer
- Sponsor
- AXOVANT
- Study code
- RVT-101-3001
- Study name
- Not specified in source
- Phase
- Phase 3
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase 3, double-blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
CREAD OLE · BN40031
- Medical area
- Alzheimer
- Sponsor
- ROCHE
- Code
- BN40031
- Study name
- CREAD OLE
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Multicenter, open-label, long-term extension study of the Phase III trials (BN29552/BN29553) of crenezumab (RO5490245) in patients with mild Alzheimer's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
CREAD2 · BN 29553
- Medical area
- Alzheimer
- Sponsor
- ROCHE
- Code
- BN 29553
- Study name
- CREAD2
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of crenezumab (RO5490245) in patients with mild Alzheimer's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
CREAD · BN 29552
- Medical area
- Alzheimer
- Sponsor
- ROCHE
- Code
- BN 29552
- Study name
- CREAD
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of crenezumab (RO5490245) in patients with mild Alzheimer's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
EMERGE · 221AD301
- Medical area
- Alzheimer
- Sponsor
- BIOGEN
- Code
- 221AD301
- Study name
- EMERGE
- Phase
- Phase 3
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aducanumab (BIIB037) in patients with early Alzheimer's disease. PI: Dr. A. Ugarte. Hospital Sant Joan de Déu, Manresa.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
DAYBREAK · I8D-MC-AZET
- Medical area
- Alzheimer
- Sponsor
- LILLY / ASTRAZENECA
- Code
- I8D-MC-AZET
- Study name
- DAYBREAK
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Randomized, double-blind, placebo-controlled, delayed-start study of LY3314814 / AZD3293 in dementia due to mild Alzheimer's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
AMARANTH · AZD3293
- Medical area
- Alzheimer
- Sponsor
- ASTRAZENECA / LILLY
- Code
- AZD3293
- Study name
- AMARANTH
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Multicenter, randomized, double-blind, placebo-controlled, parallel-group, 24-month study on the efficacy, safety, tolerability, biomarkers and pharmacokinetics of AZD3293 / LY3314814 in early-stage Alzheimer's disease. PI: Dr. A. Ugarte. Hospital Sant Joan de Déu, Manresa.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
BOEHRINGER INGELHEIM · 1289.5
- Medical area
- Alzheimer
- Sponsor
- BOEHRINGER INGELHEIM
- Study code
- 1289.5
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Multicenter, double-blind, randomized, parallel-group, placebo-controlled study investigating the efficacy, safety and tolerability of BI 409306, administered orally during a 12-week treatment period, compared with placebo in patients with Alzheimer's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
LILLY · H8A-MC-LZAX
- Medical area
- Alzheimer
- Sponsor
- LILLY
- Study code
- H8A-MC-LZAX
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Effect of passive immunization on the progression of mild Alzheimer's disease with solanezumab (LY2062430) versus placebo. PI: Dr. A. Ugarte. Hospital Sant Joan de Déu, Manresa.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
AMBAR · IG1002
- Medical area
- Alzheimer
- Sponsor
- GRIFOLS
- Code
- IG1002
- Study name
- AMBAR
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Multicenter, randomized, controlled study to evaluate the efficacy and safety of short-term plasma exchange followed by long-term plasmapheresis with infusions of human albumin combined with intravenous immunoglobulin in patients with mild to moderate Alzheimer's disease.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
LUNDBECK · LU14863
- Medical area
- Alzheimer
- Sponsor
- LUNDBECK
- Study code
- LU14863
- Study name
- Not specified in source
- Phase
- Phase 3
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase 3 multicenter, randomized, double-blind, comparative, placebo-controlled, parallel-group clinical study evaluating the efficacy and safety of Lu AE58054 in patients with mild or moderate Alzheimer's disease treated with acetylcholinesterase inhibitors. PI: Dr. A. Ugarte. Hospital Sant Joan de Déu, Manresa. PI: Hospital General de Catalunya.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Memantina · LU14861B
- Medical area
- Alzheimer
- Sponsor
- LUNDBECK
- Code
- LU14861B
- Study name
- Memantina
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Open-label extension with memantine of study 14861A (2015–2016). Collaborating investigator. PI: Dr. A. Ugarte. Hospital Sant Joan de Déu, Manresa. PI: Dr. E. Balaguer. Hospital General de Catalunya.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
LUNDBECK · LU14861A
- Medical area
- Alzheimer
- Sponsor
- LUNDBECK
- Study code
- LU14861A
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Randomized, double-blind, parallel-group, placebo-controlled study of fixed doses of Lu AE 58054 in patients with mild or moderate Alzheimer's disease treated with donepezil. PI: Dr. A. Ugarte. Hospital Sant Joan de Déu, Manresa. PI: Dr. E. Balaguer. Hospital General de Catalunya.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
LUPIN · LRP/LND101001
- Medical area
- Alzheimer
- Sponsor
- LUPIN
- Study code
- LRP/LND101001
- Study name
- Not specified in source
- Phase
- Phase 2
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Randomized, double-blind, placebo-controlled, parallel-group, comparative, multicenter, phase 2 clinical study evaluating the efficacy and safety of two doses of LND101001 monotherapy in patients with mild to moderate Alzheimer's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
EISAI · BAN2401-G000-201
- Medical area
- Alzheimer
- Sponsor
- EISAI
- Study code
- BAN2401-G000-201
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Placebo-controlled, double-blind, parallel-group dose-regimen study with Bayesian adaptive randomization design to evaluate the safety, tolerability and efficacy of BAN2401 in subjects with early Alzheimer's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
SERVIER · CL2-38093-012
- Medical area
- Alzheimer
- Sponsor
- SERVIER
- Study code
- CL2-38093-012
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase IIb multicenter, randomized study investigating the efficacy and safety of three doses of S38093 (2, 5 and 20 mg/day) versus placebo, combined with donepezil (10 mg/day) in patients with moderate Alzheimer's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
ROCHE · BP 28248
- Medical area
- Alzheimer
- Sponsor
- ROCHE
- Study code
- BP 28248
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase III multicenter, randomized, double-blind, parallel-group, placebo-controlled study investigating the efficacy and safety of RO4602522 added to background treatment with acetylcholinesterase inhibitors, donepezil or rivastigmine, in patients with moderate Alzheimer's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
GENENTECH (ROCHE) · GN 28525
- Medical area
- Alzheimer
- Sponsor
- GENENTECH (ROCHE)
- Study code
- GN 28525
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Open-label extension study evaluating the efficacy and safety of MABT5102A in patients with mild or moderate Alzheimer's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
LILLY · 140-MC-BACC
- Medical area
- Alzheimer
- Sponsor
- LILLY
- Study code
- 140-MC-BACC
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Evaluation of the safety, tolerability and pharmacodynamic effects of LY2886721 in patients with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
GENENTECH (ROCHE) · GN ABE 4869g
- Medical area
- Alzheimer
- Sponsor
- GENENTECH (ROCHE)
- Study code
- GN ABE 4869g
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial evaluating the efficacy and safety of MABT5102A in patients with mild to moderate Alzheimer's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
NOVARTIS · CAD106 A2203
- Medical area
- Alzheimer
- Sponsor
- NOVARTIS
- Study code
- CAD106 A2203
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Multicenter, randomized, double-blind, placebo-controlled, 90-week clinical trial with adaptive design in patients with mild Alzheimer's disease investigating the safety, tolerability and anti-Aβ-specific antibody response after repeated intramuscular administration of CAD106 with adjuvant.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
GSK · AVA 105640
- Medical area
- Alzheimer
- Sponsor
- GSK
- Study code
- AVA 105640
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- 36-week, double-blind, double-dummy, randomized, parallel-group study investigating the effects of rosiglitazone (extended-release tablets), donepezil and placebo as monotherapy on cognition and overall clinical response in APOE ε4-stratified subjects with mild to moderate Alzheimer's disease. PI: Dr. L. Soler-Singla. Hospital General de Catalunya.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
NOVARTIS · CENA 713-ES-02
- Medical area
- Alzheimer
- Sponsor
- NOVARTIS
- Study code
- CENA 713-ES-02
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Pilot, multicenter, randomized, double-blind, controlled, parallel study evaluating the efficacy and safety of rivastigmine versus placebo in the treatment of cognitive and non-cognitive symptoms in patients with moderate to severe Alzheimer's disease.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Alfa Bioresearch · AB 13004
- Medical area
- Progressive supranuclear palsy
- Sponsor
- Alfa Bioresearch
- Study code
- AB 13004
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase IIb / III study comparing the efficacy and safety of masitinib versus placebo in the treatment of patients with progressive supranuclear palsy.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
PASSPORT · CN 002-012 / 251PP301
- Medical area
- Progressive supranuclear palsy
- Sponsor
- BRISTOL MYERS SQUIB / BIOGEN
- Study code
- CN 002-012 / 251PP301
- Study name
- PASSPORT
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Randomized, double-blind, placebo-controlled, parallel-group trial evaluating the efficacy and safety of BMS 986168 administered intravenously in patients with progressive supranuclear palsy with an open-label extension.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
UCB · PSP003
- Medical area
- Progressive supranuclear palsy
- Sponsor
- UCB
- Study code
- PSP003
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Participant-blind, investigator-blind, placebo-controlled phase IB study evaluating the safety, tolerability and pharmacokinetics of UCB0107 in study participants with progressive supranuclear palsy (PSP).
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
NOVARTIS · CAFQ056 A2212
- Medical area
- Fragile X syndrome
- Sponsor
- NOVARTIS
- Study code
- CAFQ056 A2212
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Double-blind, randomized, placebo-controlled, parallel-group study evaluating the efficacy and safety of AFQ056 in adult patients with Fragile X syndrome.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
NOVARTIS · CAFQ056 B2214
- Medical area
- Fragile X syndrome
- Sponsor
- NOVARTIS
- Study code
- CAFQ056 B2214
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Double-blind, randomized, placebo-controlled, parallel-group study evaluating the efficacy and safety of AFQ056 in adolescent patients with Fragile X syndrome.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
NOVARTIS · CAFQ056 B2279
- Medical area
- Fragile X syndrome
- Sponsor
- NOVARTIS
- Study code
- CAFQ056 B2279
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Open-label treatment extension study evaluating the safety, efficacy and tolerability of AFQ056 in adult patients with Fragile X syndrome.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
NOVARTIS · CAFQ056 B2278
- Medical area
- Fragile X syndrome
- Sponsor
- NOVARTIS
- Study code
- CAFQ056 B2278
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Open-label treatment extension study evaluating the safety and tolerability of AFQ056 in adolescent patients with Fragile X syndrome.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
NOVARTIS
- Medical area
- Síndrome X Frágil
- Sponsor
- NOVARTIS
- Code
- Not specified in source
- Study name
- Not specified in source
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- periodos para evaluar la farmacocinética, seguridad y tolerabilidad de una dosis única oral y de dosis múltiples orales de AFQ056 en pacientes con SXF entre 5 y 11 años de edad (Cohorte 1) y entre 3 y 4 años de edad (Cohorte 2).
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
ROCHE · NP27936
- Medical area
- Fragile X syndrome
- Sponsor
- ROCHE
- Study code
- NP27936
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase II randomized, double-blind, parallel-group, placebo-controlled study investigating the efficacy and safety of RO4917523 in patients with Fragile X syndrome.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
NURON · NU-100-101
- Medical area
- Multiple sclerosis
- Sponsor
- NURON
- Study code
- NU-100-101
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase III multicenter, double-blind, randomized, placebo-controlled, parallel-group study evaluating the safety and efficacy of NU100 in patients with relapsing forms of multiple sclerosis.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
NOVARTIS · CFTY 720 D2402
- Medical area
- Multiple sclerosis
- Sponsor
- NOVARTIS
- Study code
- CFTY 720 D2402
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase II double-blind, randomized, multicenter, parallel-group study investigating structural changes in the retina and the evolution of visual function after immediate versus delayed treatment with fingolimod in patients with acute demyelinating optic neuritis.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
BIAL · IMDYVA
- Medical area
- Epilepsy
- Sponsor
- BIAL
- Study code
- IMDYVA
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Epidemiological study of depression in patients with focal epilepsy and its impact on quality of life. IMDYVA study (IMpact of Depression and quality of Life).
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
BIAL · BIA 2093-311
- Medical area
- Epilepsy
- Sponsor
- BIAL
- Study code
- BIA 2093-311
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Efficacy and safety of eslicarbazepine acetate (BIA 2-093) as monotherapy in patients with newly diagnosed partial-onset seizures: double-blind, randomized, active-comparator, parallel-group, multicenter study. PI: Dr. E. Balaguer. Hospital General de Catalunya. PI: Dr. A. Ugarte. Hospital Sant Joan de Déu, Manresa.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
UCB · SP 0980
- Medical area
- Epilepsy
- Sponsor
- UCB
- Study code
- SP 0980
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Efficacy and safety of lacosamide in drug-resistant epilepsy. PI: Dr. Antonio Ugarte. Hospital Sant Joan de Déu, Manresa.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
ASTRA · CLASS
- Medical area
- Cerebrovascular disease
- Sponsor
- ASTRA
- Study code
- CLASS
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Neuroprotection with chlormethiazole in acute stroke, double-blind, placebo-controlled, 6 to 12 hours after onset. PI: Dr. L. Soler-Singla. Hospital General de Catalunya.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
URIACH · TACIP
- Medical area
- Cerebrovascular disease
- Sponsor
- URIACH
- Study code
- TACIP
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Triflusal versus acetylsalicylic acid in secondary prevention of ischemic stroke. PI: Dr. L. Soler-Singla. Hospital General de Catalunya.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
BOEHRINGER-INGELHEIM · BI 248.604
- Medical area
- Restless legs syndrome
- Sponsor
- BOEHRINGER-INGELHEIM
- Study code
- BI 248.604
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Randomized study evaluating the efficacy and safety of pramipexole versus placebo in restless legs syndrome and mood disturbance.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
BOEHRINGER-INGELHEIM · BI 248.615
- Medical area
- Restless legs syndrome
- Sponsor
- BOEHRINGER-INGELHEIM
- Study code
- BI 248.615
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Randomized study evaluating the efficacy and safety of pramipexole versus placebo in restless legs syndrome and sleep disturbance.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
BOEHRINGER-INGELHEIM · BI 248.641
- Medical area
- Tourette syndrome
- Sponsor
- BOEHRINGER-INGELHEIM
- Study code
- BI 248.641
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase III double-blind, double-dummy, placebo-controlled, 8-week fixed-dose trial with pramipexole IR (Mirapex®, Mirapexin®, Pexola®, Sifrol®) 0.125 and 0.5 mg/day administered orally to investigate the efficacy and safety in patients 6-17 years of age diagnosed with Tourette syndrome according to DSM-IV criteria.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
OTSUKA · 31-12-293
- Medical area
- Tourette syndrome
- Sponsor
- OTSUKA
- Study code
- 31-12-293
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of aripiprazole administered as fixed oral once-daily doses in children and adolescents with Gilles de la Tourette syndrome.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
CB-01-11/28 · CRO-16-130 S
- Medical area
- Ensayos clínicos no neurológicos
- Sponsor
- COSMO
- Code
- CRO-16-130 S
- Study name
- CB-01-11/28
- Phase
- No especificada en origen
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Phase II multicenter, randomized, double-blind, placebo-controlled proof-of-concept study of the efficacy and safety of 600 mg Rifamycin SV-MMX® tablets administered two or three times daily in patients with irritable bowel syndrome with predominant diarrhea.
- Status
- Historical
- Information for patients
- Contact UDIC.
- Information for healthcare professionals
- Information available pending validation by the UDIC team.
LEON FARMA · CF 111/302
- Medical area
- Non-neurological clinical trials
- Sponsor
- LEON FARMA
- Study code
- CF 111/302
- Study name
- Not specified in source
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Pivotal phase III multicenter, double-blind, double-dummy, randomized study comparing contraceptive efficacy, tolerability and safety of LF111 (drospirenone) over 9 cycles with Cerazette (desogestrel 0.075 mg).
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
PERSPECTIVE · CLCZ696B2320
- Medical area
- Non-neurological clinical trials
- Sponsor
- NOVARTIS
- Study code
- CLCZ696B2320
- Study name
- PERSPECTIVE
- Phase
- Not specified in source
- Intervention / treatment
- Consultar protocolo con UDIC.
- Description
- Multicenter, randomized, double-blind, active-treatment-controlled study evaluating the effects of LCZ696 compared with valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction.
- Status
- Archived trial
- Information for patients
- Please contact UDIC.
- Information for professionals
- Information available subject to validation by the UDIC team.
Move window